Breaking News Instant updates and real-time market news.

BOLD

Audentes Therapeutics

$35.53

1.62 (4.78%)

10:22
01/04/18
01/04
10:22
01/04/18
10:22

Piper ups Audentes target to $45 on 'far' better than expected data

Piper Jaffray analyst Christopher Raymond raised his price target for Audentes Therapeutics to $45 from $36 saying the initial data for AT132 in X-Linked Myotubular Myopathy is "far" better than expected." The stock in morning trading is up 13% to $40.08. While elevated troponin levels seen in one patient is noteworthy, mitigating circumstances, combined with "truly remarkable efficacy," more than offsets this concern, Raymond tells investors in a research note. The analyst believes six month data next quarter is likely to solidify AT132's therapeutic premise. He remains a buyer of Audentes shares with an Overweight rating.

  • 04

    Jan

BOLD Audentes Therapeutics
$35.53

1.62 (4.78%)

11/15/17
LEER
11/15/17
NO CHANGE
Target $29
LEER
Outperform
Audentes Therapeutics price target raised to $29 from $22 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Audentes Therapeutics to $29 from $22 saying it has made significant progress with upcoming catalysts for AT132 and AT342. Larger programs are also advancing towards IND filing, both of which are expected to occur in 2018, he adds. The analyst reiterates an Outperform rating on the shares.
12/05/17
BMOC
12/05/17
INITIATION
Target $35
BMOC
Outperform
Audentes Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini started Audentes Therapeutics with an Outperform rating and $35 price target. The company is an "emerging" gene therapy company focused on treating rare diseases with few or no treatment options, the analyst tells investors in a research note. He believes its pipeline provides opportunities for long-term upside.
12/12/17
PIPR
12/12/17
NO CHANGE
Target $36
PIPR
Overweight
Audentes Therapeutics stock to run further on AT132 data, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Audentes Therapeutics with an Overweight rating and a price target of $36. Raymond says that despite the 56% year-to-date price gain, shares are "poised for another leg higher" on initial human data on lead program AT132 next month and second program AT342 for Crigler Najjar starting to dose patients in its Phase 1/2 VALENS study in Q1 of 2018.
12/20/17
HCWC
12/20/17
INITIATION
Target $37
HCWC
Buy
Audentes Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Audentes Therapeutics with a Buy rating and $37 price target. The analyst views the company's market positioning in AAV-based gene therapy as compelling and believes 2018 is "catalyst-filled."

TODAY'S FREE FLY STORIES

DE

Deere

$145.63

7.14 (5.16%)

10:37
11/21/18
11/21
10:37
11/21/18
10:37
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere raises 2022…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

DE

Deere

$144.30

5.81 (4.20%)

10:32
11/21/18
11/21
10:32
11/21/18
10:32
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere sees grain demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

10:31
11/21/18
11/21
10:31
11/21/18
10:31
General news
Crude inventories for week of November 16 »

Crude oil inventories…

JNJ

Johnson & Johnson

$143.12

-3.32 (-2.27%)

10:30
11/21/18
11/21
10:30
11/21/18
10:30
Options
J&J puts active as shares see relative weakness »

J&J puts active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

10:30
11/21/18
11/21
10:30
11/21/18
10:30
General news
FX Action: The dollar »

FX Action: The dollar…

DE

Deere

$143.26

4.77 (3.44%)

10:29
11/21/18
11/21
10:29
11/21/18
10:29
Hot Stocks
Deere says U.S. farmers, dealers 'cautiously optimistic' »

Says record yields,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

AVGO

Broadcom

$229.32

1.63 (0.72%)

, VLKAY

Volkswagen

$0.00

(0.00%)

10:28
11/21/18
11/21
10:28
11/21/18
10:28
Periodicals
Breaking Periodicals news story on Broadcom, Volkswagen »

Broadcom said to settle…

AVGO

Broadcom

$229.32

1.63 (0.72%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMZN

Amazon.com

$1,520.59

24.99 (1.67%)

10:27
11/21/18
11/21
10:27
11/21/18
10:27
Periodicals
Amazon contacting some users about error that exposed emails, The Verge says »

Amazon has been emailing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

10:25
11/21/18
11/21
10:25
11/21/18
10:25
General news
U.S. leading index rose 0.1% to 112.1 in October, another record high »

U.S. leading index rose…

TLC

Taiwan Liposome

$0.00

(0.00%)

10:21
11/21/18
11/21
10:21
11/21/18
10:21
Syndicate
Taiwan Liposome opens at $6.06, IPO priced at $5.80 per share »

Taiwan Liposome (TLC)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NVDA

Nvidia

$150.33

1.19 (0.80%)

10:20
11/21/18
11/21
10:20
11/21/18
10:20
Technical Analysis
Technical Take: Nvidia goes negative on the day »

At time of writing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
U.S. October existing home sales bounced 1.4% to 5.220 M »

U.S. October existing…

JD

JD.com

$20.24

0.75 (3.85%)

10:20
11/21/18
11/21
10:20
11/21/18
10:20
Options
Third day of call buying in JD »

Third day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
Treasury Action: yields steadied above lows »

Treasury Action: yields…

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
The Michigan sentiment drop »

The Michigan sentiment…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/21/18
11/21
10:17
11/21/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/21/18
11/21
10:16
11/21/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
11/21/18
11/21
10:15
11/21/18
10:15
General news
Breaking General news story  »

Week of 11/16 EIA…

WDC

Western Digital

$46.68

0.99 (2.17%)

10:10
11/21/18
11/21
10:10
11/21/18
10:10
Options
Western Digital weekly calls active as shares gain 3% »

Western Digital weekly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

10:10
11/21/18
11/21
10:10
11/21/18
10:10
General news
U.S. consumer sentiment fell 1.1 points to 97.5 in the final November print »

U.S. consumer sentiment…

BGNE

BeiGene

$126.50

0.63 (0.50%)

, GMDA

Gamida Cell

$9.50

(0.00%)

10:09
11/21/18
11/21
10:09
11/21/18
10:09
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

BGNE

BeiGene

$126.50

0.63 (0.50%)

GMDA

Gamida Cell

$9.50

(0.00%)

MRKR

Marker Therapeutics

$6.37

0.11 (1.76%)

ARCE

Arco Platform

$22.65

(0.00%)

NVT

nVent Electric

$24.43

0.25 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 01

    Dec

  • 03

    Dec

  • 07

    Dec

LOW

Lowe's

$86.80

0.65 (0.75%)

, GS

Goldman Sachs

$193.69

2.35 (1.23%)

10:09
11/21/18
11/21
10:09
11/21/18
10:09
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…

LOW

Lowe's

$86.80

0.65 (0.75%)

GS

Goldman Sachs

$193.69

2.35 (1.23%)

CS

Credit Suisse

$11.93

0.21 (1.79%)

SWGAY

Swatch Group

$0.00

(0.00%)

LNT

Alliant Energy

$44.64

-0.62 (-1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

BBY

Best Buy

$62.39

-1.15 (-1.81%)

, WIX

Wix.com

$87.71

1.55 (1.80%)

10:09
11/21/18
11/21
10:09
11/21/18
10:09
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…

BBY

Best Buy

$62.39

-1.15 (-1.81%)

WIX

Wix.com

$87.71

1.55 (1.80%)

RP

RealPage

$47.36

1.59 (3.47%)

TNDM

TNDM

EIX

Edison International

$53.57

0.77 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

10:07
11/21/18
11/21
10:07
11/21/18
10:07
General news
Market sees early gains as averages bounce off three-week lows »

Stock futures moved…

SCOR

comScore

$16.17

0.11 (0.68%)

10:06
11/21/18
11/21
10:06
11/21/18
10:06
Conference/Events
UBS U.S. Internet analyst to hold an analyst/industry conference call »

U.S. Internet Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.